Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
OPEN BMC psychiatry | 16 Nov 2016
G Malaguarnera, G Bertino, G Chisari, M Motta, M Vecchio, M Vacante, F Caraci, C Greco, F Drago, G Nunnari and M Malaguarnera
Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b (Peg-IFN) and Ribavirin (RBV).
* Data courtesy of Altmetric.com